Arrowhead Pharmaceuticals Inc
ARWR64.520USD
-0.120-0.19%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
8.86BCap. mercado
40.35P/E TTM
Más Datos de Arrowhead Pharmaceuticals Inc Compañía
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Información de Arrowhead Pharmaceuticals Inc
Símbolo de cotizaciónARWR
Nombre de la empresaArrowhead Pharmaceuticals Inc
Fecha de salida a bolsaDec 14, 1993
Director ejecutivoAnzalone (Christopher Richard)
Número de empleados711
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 14
Dirección177 E Colorado Blvd
CiudadPASADENA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91105
Teléfono16266964702
Sitio Webhttps://arrowheadpharma.com/
Símbolo de cotizaciónARWR
Fecha de salida a bolsaDec 14, 1993
Director ejecutivoAnzalone (Christopher Richard)
Ejecutivos de Arrowhead Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-13187.00%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+23007.00%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
63.01K
+8027.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+12801.00%
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
35.72K
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
33.60K
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Lead Independent Director
Lead Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-13187.00%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+23007.00%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
63.01K
+8027.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+12801.00%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.12%
The Vanguard Group, Inc.
10.90%
Avoro Capital Advisors LLC
7.78%
State Street Investment Management (US)
4.57%
Fidelity Management & Research Company LLC
4.11%
Otro
59.52%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.12%
The Vanguard Group, Inc.
10.90%
Avoro Capital Advisors LLC
7.78%
State Street Investment Management (US)
4.57%
Fidelity Management & Research Company LLC
4.11%
Otro
59.52%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.69%
Investment Advisor/Hedge Fund
27.59%
Hedge Fund
8.16%
Individual Investor
3.80%
Research Firm
2.44%
Sovereign Wealth Fund
1.39%
Pension Fund
0.99%
Bank and Trust
0.35%
Venture Capital
0.18%
Otro
13.42%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
591
114.80M
88.39%
+9.71K
2025Q3
611
114.80M
88.75%
+6.59M
2025Q2
590
107.34M
86.27%
+533.10K
2025Q1
582
106.99M
81.94%
-5.53M
2024Q4
591
101.33M
89.06%
+682.02K
2024Q3
588
101.78M
87.03%
+1.24M
2024Q2
591
100.85M
86.00%
+921.50K
2024Q1
603
99.92M
69.60%
+13.68M
2023Q4
610
81.59M
77.27%
+3.47M
2023Q3
608
78.04M
73.69%
+2.79M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
18.37M
13.52%
+771.04K
+4.38%
Sep 30, 2025
The Vanguard Group, Inc.
16.01M
11.79%
+510.80K
+3.30%
Sep 30, 2025
Avoro Capital Advisors LLC
10.90M
8.03%
+300.00K
+2.83%
Sep 30, 2025
State Street Investment Management (US)
6.40M
4.71%
+26.31K
+0.41%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.76M
4.24%
+589.26K
+11.40%
Sep 30, 2025
Slate Path Capital LP
4.98M
3.67%
-250.00K
-4.78%
Sep 30, 2025
Anzalone (Christopher Richard)
3.81M
2.8%
-115.33K
-2.94%
Dec 29, 2025
Geode Capital Management, L.L.C.
3.13M
2.31%
+152.54K
+5.12%
Sep 30, 2025
Invus Public Equities Advisors, LLC
2.67M
1.97%
--
--
Sep 30, 2025
Driehaus Capital Management, LLC
2.10M
1.55%
+1.49M
+244.15%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Global X Genomics & Biotechnology ETF
5.45%
Invesco S&P SmallCap Health Care ETF
3.59%
ROBO Global Healthcare Technology & Innovation ETF
3.41%
ALPS Medical Breakthroughs ETF
2.38%
Tema Heart & Health ETF
2.18%
Invesco Dorsey Wright Healthcare Momentum ETF
1.89%
Virtus LifeSci Biotech Clinical Trials ETF
1.77%
State Street SPDR S&P Biotech ETF
1.18%
First Trust Small Cap Growth AlphaDEX Fund
1.1%
WisdomTree BioRevolution Fund
1.08%
Ver más
Global X Genomics & Biotechnology ETF
Proporción5.45%
Invesco S&P SmallCap Health Care ETF
Proporción3.59%
ROBO Global Healthcare Technology & Innovation ETF
Proporción3.41%
ALPS Medical Breakthroughs ETF
Proporción2.38%
Tema Heart & Health ETF
Proporción2.18%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.89%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.77%
State Street SPDR S&P Biotech ETF
Proporción1.18%
First Trust Small Cap Growth AlphaDEX Fund
Proporción1.1%
WisdomTree BioRevolution Fund
Proporción1.08%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
